Horizon Therapeutics said to be fielding $20 billion takeover interest, reveals the Wall Street Journal

Biopharmaceutical dealmaking is back in vogue and hacks at the Wall Street Journal have dug out the latest scoop.

You need to register and sign in to read this content.